Role of calcium channel blockers in the future, in view of the insight study

Kidney International, Supplement

Volumn 62, Issue 82, 2002, Pages

  Rosenthal, Talma ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Dihydropyridine formulations; Diuretics; Hypertension treatment; Nifedipine; Norepinephrine; Sympathetic system

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LACIDIPINE; NIFEDIPINE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANKLE EDEMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MEGADOSE; DRUG RESEARCH; FAMILY HISTORY; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; METABOLISM; MORTALITY; PRIORITY JOURNAL; SMOKING; STROKE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MIDDLE AGED; NIFEDIPINE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036434436     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.62.s82.7.x     Document Type: Conference Paper

References (22)

1. Tobian L, Brunner HR, Cohn JN, et al: Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guideline. Am J Hypertens 7:859-872, 1994
2. Brown MB, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomised to double blind treatment with a long acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366-372, 2000
3. Mancia G, Grassi G: The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. Am J Cardiol 82:23R-28R, 1998
4. Hansson L, Lindholm L, Ekbom T, et al: Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study. Lancet 354:1751-1756, 1999
5. Hansson L, Hedner T, Lund-Johansen P, et al: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The NORDIC Diltiazem (Nordil) study. Lancet 356:359-365, 2000
6. De Champlain J, Karas M, Nguyen P, et al: Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 16:1357-1369, 1998
7. DeQuattro V, Lee DP. Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: Disparate effects on neurohormones and ambulatory blood pressure and the influence of salt. Cardiology 88(Suppl 3):38-42, 1997
8. Parving HH, Tarnow L, Rossing P: Renal protection in diabetes: An emerging role for calcium antagonists. Hypertension 14(Suppl):S21-S25, 1996
9. Tuomilehto J, Rastenyte D, Birkenhager WH, et al: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340:677-684, 1999
10. Brown MJ, Castaigne A, De Leeuw PW, et al: Influence of diabetes and type of hypertension on the response to antihypertensive treatment. Hypertension 35:1038-1042, 2000
11. Jollis JG, Simpson RJ, Jr, Chowdhury MK, et al: Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch Intern Med 159:2341-2348, 1999
12. Pahor M, Psaty BM, Alderman MH, et al: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomized controlled trials. Lancet 356:1949-1954, 2000
13. Opie LH: Calcium channel blockers in hypertension: Reappraisal after new trials and major meta-analyses. Am J Hypertens 14:1074-1081, 2001
14. Motro M, Shemesh J: Calcium channel blocker. Nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 37:1410-1413, 2001
15. Simon A, Gariepy J, Moyse D, Levenson J: Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 103:2949-2954, 2001
16. Schiffrin EL: Structure and function of small arteries of essential hypertensive patients following chronic treatment with once a day nifedipine. Cardiology 88(Suppl 3):20-26, 1997
17. Testa MA, Turner RR: Assessment of quality of life in hypertension and its bearing on compliance. IJCP (Suppl 92):19-22, 1997
18. Pascale A, Etcheberrigaray R: Calcium alterations in Alzheimer's disease: Pathophysiology, models and therapeutic opportunities. Pharmacol Res 39:81-88, 1999
19. Pessina AC, Boari L, De Dominicis E, et al: Efficacy, tolerability and influence on "quality of life" of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension. Blood Press 10:176-183, 2001
20. Gradman AH, Cutler NR, Davis PJ, et al: Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-felodipine ER Factorial Study Group. Am J Cardiol 79:431-435, 1997
21. Mancia G. Closing remarks. INSIGHT proceedings of a symposium. IJCP 92(Suppl):76, 1997
22. Van Zwieten PA, Hansson L: Calcium antagonists and safety: The turning of the tide. Blood Press 8:5-8, 1999